These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 33390267)

  • 1. Brain metastasis in head and neck squamous cell carcinoma after immune check point inhibitors treatment.
    Lorini L; Merlano M; Licitra L; Ravanelli M; Bossi P
    Oral Oncol; 2021 May; 116():105138. PubMed ID: 33390267
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapeutic Approaches With Immune Checkpoint Inhibitors in Head and Neck Cancers and the Role of PD-L1 as a Biomarker.
    Oualla K; Castelo Branco L; Nouiyakh L; Amaadour L; Benbrahim Z; Arifi S; Mellas N
    Cancer Control; 2021; 28():10732748211004878. PubMed ID: 33827280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint inhibitor use in head and neck squamous cell carcinoma: the current landscape and future perspectives.
    Gatfield ER; Tadross J; Ince W
    Future Oncol; 2024; 20(23):1695-1711. PubMed ID: 38889284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Letter to the Editor: "Exploring long-term responses to immune checkpoint inhibitors in recurrent and metastatic head and neck squamous cell Carcinoma".
    Haridevamuthu B
    Oral Oncol; 2024 Sep; 156():106913. PubMed ID: 38955109
    [No Abstract]   [Full Text] [Related]  

  • 5. No prime time yet for checkpoint inhibitors in localised head and neck squamous cell carcinoma.
    Voortman J
    Lancet Oncol; 2024 May; 25(5):533-534. PubMed ID: 38697152
    [No Abstract]   [Full Text] [Related]  

  • 6. Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12.
    Lee YG; Chang H; Keam B; Chun SH; Park J; Park KU; Shin SH; An HJ; Lee KE; Lee KW; Kim HR; Kim SB; Ahn MJ; Hwang IG
    Cancer Res Treat; 2021 Jul; 53(3):671-677. PubMed ID: 33285051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current landscape of immunotherapy trials in locally advanced and high-risk head and neck cancer.
    Park R; Park JC
    Immunotherapy; 2021 Aug; 13(11):931-940. PubMed ID: 34100301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma: Combination immunotherapy.
    Vathiotis IA; Johnson JM; Argiris A
    Cancer Treat Rev; 2021 Jun; 97():102192. PubMed ID: 33819755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea.
    Kim H; Kwon M; Kim B; Jung HA; Sun JM; Lee SH; Park K; Ahn MJ
    BMC Cancer; 2020 Aug; 20(1):727. PubMed ID: 32758163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positron Emission Tomography-Computed Tomography Imaging, Genomic Profile, and Survival in Patients With Head and Neck Cancer Receiving Immunotherapy.
    Fitzgerald CWR; Valero C; Swartzwelder CE; Morris LGT
    JAMA Otolaryngol Head Neck Surg; 2021 Dec; 147(12):1119-1120. PubMed ID: 34297796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-treatment tumor size impacts on response to nivolumab in head and neck squamous cell carcinoma.
    Inoue H; Yokota T; Hamauchi S; Onozawa Y; Kawakami T; Shirasu H; Notsu A; Yasui H; Onitsuka T
    Auris Nasus Larynx; 2020 Aug; 47(4):650-657. PubMed ID: 32035695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio during immune checkpoint inhibitor treatment in recurrent or metastatic head and neck squamous cell carcinoma patients.
    Li JL; Hsieh TL; Ou MC; Lin FC; Tsai SC
    Oral Oncol; 2022 Mar; 126():105729. PubMed ID: 35144206
    [No Abstract]   [Full Text] [Related]  

  • 13. The value and inadequacy of tumor mutation burden on efficacy of immune checkpoint inhibitors in head and neck cancers.
    Ma HH; Chen DS; Li S; Xiao MZ; Qi C
    Oral Oncol; 2021 Jun; 117():105179. PubMed ID: 33514453
    [No Abstract]   [Full Text] [Related]  

  • 14. Radiologic predictors of immune checkpoint inhibitor response in advanced head and neck squamous cell carcinoma.
    Sridharan V; Rahman RM; Huang RY; Chau NG; Lorch JH; Uppaluri R; Haddad RI; Hanna GJ; Schoenfeld JD
    Oral Oncol; 2018 Oct; 85():29-34. PubMed ID: 30220316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel comprehensive immune-related gene signature as a promising survival predictor for the patients with head and neck squamous cell carcinoma.
    Fang R; Iqbal M; Chen L; Liao J; Luo J; Wei F; Wen W; Sun W
    Aging (Albany NY); 2021 Apr; 13(8):11507-11527. PubMed ID: 33867351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A predictive survival model for patients with head and neck squamous cell carcinoma treated with immune check point inhibitors.
    Bonomi M; Bhateja P; Issa M; Klamer B; Pan X; Blakaj A; Karivedu V; Mousa L; Mitchell D; Gamez M; Kang S; Seim NB; Old M; Carrau R; Rocco J; Blakaj D
    Oral Oncol; 2020 Nov; 110():104900. PubMed ID: 32702630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
    Suzuki S; Toyoma S; Kawasaki Y; Koizumi K; Iikawa N; Shiina K; Endo T; Abe T; Kouga T; Yamada T
    Medicina (Kaunas); 2021 Oct; 57(11):. PubMed ID: 34833369
    [No Abstract]   [Full Text] [Related]  

  • 18. The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer.
    Qiao XW; Jiang J; Pang X; Huang MC; Tang YJ; Liang XH; Tang YL
    Front Immunol; 2020; 11():1721. PubMed ID: 33072064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging immune checkpoint inhibitors for the treatment of head and neck cancers.
    Green SE; McCusker MG; Mehra R
    Expert Opin Emerg Drugs; 2020 Dec; 25(4):501-514. PubMed ID: 33196319
    [No Abstract]   [Full Text] [Related]  

  • 20. Tumorigenic potential of GLUT4: A therapeutic target for head and neck squamous cell carcinoma.
    Prasad M; Veeraraghavan VP; Jayaraman S
    Oral Oncol; 2022 Oct; 133():106061. PubMed ID: 35952585
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.